Not yet recruitingPHASE3INTERVENTIONAL

A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

This research study is testing a new combination medicine, EloraTZP, for adults who are living with obesity and do not have type 2 diabetes. The main goal is to find out if EloraTZP is safe and effective at helping people lose weight. Researchers will compare it to two single medicines (eloralintide and tirzepatide) and a dummy treatment, called a placebo. By comparing these, the study aims to understand the best way to help people manage their weight. Taking part would last about two years, and it's a 'Phase 3' study, which means it's one of the final steps before a new medicine could potentially become widely available.

At a glance

Status

Not yet recruiting

Phase

PHASE3

Sponsor

Eli Lilly and Company

Enrolment target

2,115

Start

01 Dec 2026

Estimated completion

01 Nov 2029

Obesity

What is this study about?

This study is looking into a new way to help adults who are living with obesity. It's focused on a new combination medicine called EloraTZP. The researchers want to see if this new treatment can help people lose weight safely and effectively. They will compare it to two individual medicines, eloralintide and tirzepatide, and also to a 'placebo'. A placebo is a dummy treatment that looks like the real medicine but contains no active ingredients. This helps researchers understand if the new treatment works better than nothing at all.

Finding new ways to manage obesity is very important because it can affect your health in many ways. This study is specifically for people who do not have type 2 diabetes, as many weight loss studies often include people with diabetes. By doing this research, scientists hope to find better options for people in the UK and worldwide to improve their health and well-being.

This is a 'Phase 3' study, which is an important step in developing new medicines. It means the treatment has already been tested in smaller groups and is now being looked at in a larger number of people to confirm its benefits and understand any potential side effects before it could be approved for general use.

Key takeaways

This study is testing a new combination medicine (EloraTZP) for obesity in adults.
It's for people who do not have type 2 diabetes.
The study compares EloraTZP with other treatments and a dummy medicine (placebo).
Participation would last for about two years with regular health check-ups.
It's a 'Phase 3' study, aiming to find safer and more effective weight loss options.
You can stop participating at any time.

Who may be eligible?

To join this study, you need to be an adult (18 years or older) and living with obesity. This usually means having a Body Mass Index (BMI) of 35 or more. You also need to have tried to lose weight through diet at least once before, without lasting success. It's important that your weight has been generally stable for the last three months, without big ups or downs.

There are also some reasons why you might not be able to join. For example, if you have type 1 or type 2 diabetes, or any other type of diabetes, this study isn't for you. You also couldn't take part if you've recently had a serious heart problem (like a heart attack or stroke in the last three months), or if you have severe heart failure. If you've had weight-loss surgery or certain other procedures for weight loss, or if you've recently used other weight-loss medicines, you also wouldn't be eligible. The study team will carefully check all these details to make sure it's safe and right for you to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a Body Mass Index (BMI) of 35 or more?
Have you tried to lose weight through diet in the past?
Do you NOT have type 1 or type 2 diabetes?
Have you NOT had a heart attack, stroke, or severe heart failure in the last 3 months?
Have you NOT had weight-loss surgery or used other weight-loss medicines recently?

Answer every question to see your result.

What does participation involve?

If you decide to join this study, it would last for about two years. During this time, you would have regular visits to the clinic. At these visits, the study team would give you the study medicine (either EloraTZP, one of the individual medicines, or the placebo). You would also have check-ups, which might include blood tests, measuring your weight, and checking your general health to see how you're getting on and if the treatment is helping.

It's important to remember that you wouldn't know which treatment you are receiving (the actual medicine or the placebo) because the study is 'blinded'. This helps make sure the results are fair. The study team will provide all the necessary care related to the trial and will be there to answer any questions you have throughout your participation.

Potential risks and benefits

Taking part in a study like this could offer potential benefits, such as receiving a new combination treatment for obesity or close medical monitoring of your health. However, like all medicines, the treatments being tested might have side effects. These could range from mild to more serious, and the study team will discuss all known possibilities with you. It's very important to remember that you are a volunteer, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (155)

Care Access - 801 South Power Road, Mesa
Verified postcode
Mesa, United States
Headlands Research - Scottsdale
Verified postcode
Scottsdale, United States
Tucson Clinical Research Institute
Verified postcode
Tucson, United States
Valley Clinical Trials, Inc.
Verified postcode
Covina, United States
Los Angeles Institute for Metabolic Research
Verified postcode
Los Angeles, United States
Peninsula Research Associates
Verified postcode
Rolling Hills Estates, United States
Artemis Institute for Clinical Research
Verified postcode
San Diego, United States
Southern California Clinical Research
Verified postcode
Santa Ana, United States
Yale University School of Medicine
Verified postcode
New Haven, United States
JEM Research Institute
Verified postcode
Atlantis, United States
K2 Medical Research - Maitland
Verified postcode
Maitland, United States
Flourish Research - Miami, LLC
Verified postcode
Miami, United States

Common questions

What is obesity and why is it important to treat?

Obesity means carrying too much body fat, which can affect your health in many ways, like increasing your risk of heart problems, stroke, and certain cancers. Finding effective treatments helps people live healthier lives.

What is a 'placebo'?

A placebo is a dummy treatment that looks exactly like the real medicine but contains no active ingredients. It's used in studies to help researchers see if the actual medicine works better than just a fake treatment.

Will I know if I'm getting the real medicine or the placebo?

No, in this study, neither you nor the study doctors will know whether you're getting the active medicine or the placebo. This is called 'blinding' and it helps make the study results as fair and accurate as possible.

How long will I be in the study?

If you decide to join, your participation in the study would last for about two years.

Can I leave the study if I change my mind?

Yes, absolutely. You are a volunteer and can choose to leave the study at any time, for any reason, without having to explain why. It won't affect your future medical care.

How to find out more

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

lillytrials@lilly.com 317-615-4559 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.